Aster DM Healthcare
Aster DM Quality Care Ltd
- Market Cap
- ₹67,929 Cr
- P/E
- 110.70
Key Fundamentals
MidcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 11.60%
- Debt to Equity
- 0.76
- EPS (TTM)
- ₹7.04
- Book Value
- ₹89.38
- Market Cap
- ₹67,929 Cr
- P/E (TTM)
- 110.70
- P/B
- 8.72
- ROE
- 11.30%
- Dividend Yield
- 0.41%
- EBITDA
- ₹1,027 Cr
- 52W High
- ₹891.30
- 52W Low
- ₹519.10
- Day Range
- ₹729.00 – ₹781.85
- Volume
- 26,65,994
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 30
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 35
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 33
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 18
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 96
- Strong
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 1,560%
- Promoter holding has increased by 13.4% over last quarter.
Weaknesses
4- Stock is trading at 8.72 times its book value
- Company has a low return on equity of 8.46% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 67.0% of their holding.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 5 | 12 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 65.83
- Neutral
- MACD (12,26,9)
- 14.24
- Bullish
- SMA (50)
- 713.85
- Bullish
- SMA (200)
- 724.74
- Bullish
As of
Analyst Rating
12 of 12 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | −1.22% |
|---|---|
| 5Y | −11.61% |
| 3Y | +15.75% |
| 1Y | +12.20% |
| TTM | +50.47% |
Net profit
| 10Y | +48.84% |
|---|---|
| 5Y | +19.12% |
| 3Y | −3.49% |
| 1Y | −92.10% |
| TTM | +54.52% |
Operating cash flow
| 10Y | +12.45% |
|---|---|
| 5Y | −16.00% |
| 3Y | −29.01% |
| 1Y | +54.35% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +10.37 pp |
|---|---|
| 5Y | +6.04 pp |
| 3Y | +3.92 pp |
| 1Y | +0.58 pp |
| TTM | +1.90 pp |
Revenue by year
| Mar 2017 | ₹5,931 Cr |
|---|---|
| Mar 2018 | ₹6,721 Cr |
| Mar 2019 | ₹7,963 Cr |
| Mar 2020 | ₹8,652 Cr |
| Mar 2021 | ₹8,608 Cr |
| Mar 2022 | ₹10,253 Cr |
| Mar 2023 | ₹2,994 Cr |
| Mar 2024 | ₹3,699 Cr |
| Mar 2025 | ₹4,138 Cr |
| Mar 2026 | ₹4,643 Cr |
Net profit by year
| Mar 2017 | ₹98.00 Cr |
|---|---|
| Mar 2018 | ₹282 Cr |
| Mar 2019 | ₹367 Cr |
| Mar 2020 | ₹315 Cr |
| Mar 2021 | ₹178 Cr |
| Mar 2022 | ₹601 Cr |
| Mar 2023 | ₹475 Cr |
| Mar 2024 | ₹212 Cr |
| Mar 2025 | ₹5,408 Cr |
| Mar 2026 | ₹427 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Aster DM Healthcare trades at ₹739.3 as of 2026-11-19 with a market cap of ₹64,443 Cr. The stock commands a PE of 105x TTM earnings and 8.66x book value, reflecting premium valuations, while TTM sales growth of 50% and profit growth of 43% show a strong recent rebound. However, a 3-year profit CAGR of -1% and promoter pledge of 67% introduce meaningful risk factors.
- TTM revenue growth of 50% signals a sharp acceleration in the top line, well above the 3-year sales CAGR of 16%
- TTM profit growth of 43% demonstrates a strong earnings recovery after a flat 3-year profit CAGR of -1%
- Promoter holding increased by 13.4% over the last quarter, indicating meaningful insider confidence at current levels
- 5-year stock CAGR of 30% and 3-year stock CAGR of 30% reflect sustained long-term wealth creation for shareholders
- 10-year compounded profit growth of 48% highlights a strong long-term earnings trajectory despite interim volatility
- Debt-to-equity ratio of 0.62 is moderate and manageable for a capital-intensive healthcare business
- The company has maintained a healthy dividend payout of 1,560%, returning significant capital to shareholders
- Last year ROE of 11% shows improvement over the 3-year average ROE of 8% and 10-year average of 9%
- Promoters have pledged 67.0% of their holding, creating significant risk of forced selling in a downturn
- Price-to-book of 8.66x is steep and well above typical healthcare sector averages, pricing in aggressive future expectations
- 3-year compounded profit growth of -1% indicates earnings stagnated over a meaningful medium-term window
- 5-year compounded sales growth of -12% reflects a period of significant revenue contraction, likely tied to the GCC divestment
- 3-year average ROE of approximately 8% and current ROE of 8.84% are modest for a stock trading at such premium valuations
- ROCE of 9.71% suggests the business earns only a thin spread over its cost of capital, questioning the premium multiple
- The stock trades 17% below its 52-week high of ₹891.3 but 42% above its 52-week low of ₹519.1, suggesting volatility risk persists
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet period for Aster DM with only housekeeping corporate actions — a loan-to-equity conversion in a subsidiary, a board appointment, and post-merger fractional share settlements. No material positive catalysts or red flags emerged. The ₹102.46 Cr equity conversion in Sri Sainatha signals continued commitment to its subsidiary but carries no immediate P&L impact. Investors should watch for upcoming quarterly results and operational updates for directional cues.
- ₹102 Cr loan converted to equity Nov 06
Board approved conversion of ₹102.46 Cr intercompany loan to subsidiary Sri Sainatha into equity and terminated agreements with DMERF.
- Independent director appointment sought Nov 12
Postal ballot issued to approve Neela Bhattacharjee as Non-Executive Independent Director for a three-year term ending September 2029.
- Fractional share payouts certified Nov 09
Audit Committee certified distribution of net sale proceeds from consolidated fractional shares to eligible shareholders of Quality Care India Limited post-amalgamation.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 | 1,186 | 1,182 | 1,311 | 2,829 |
| Expenses | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 | 983 | 958 | 1,055 | 2,174 |
| Operating Profit | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 | 202 | 224 | 256 | 655 |
| OPM % | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% | 17% | 19% | 20% | 23% |
| Other Income | −64 | 153 | −40 | 5,120 | 35 | 32.99 | 31.28 | 29 | 28 | 0 | 37 | 37.03 | 51.53 |
| Interest | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 | 31 | 30 | 31 | 119 |
| Depreciation | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 | 68 | 67 | 69 | 150 |
| Exceptional Items | — | — | — | — | — | −23.72 | −26.42 | — | — | — | — | −114 | −18.95 |
| PBT | −7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 | 103 | 163 | 78 | 419 |
| Tax % | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% | 43% | 6% | 62% | 23% |
| Net Profit | −15 | 209 | −2 | 5,152 | 106 | 64 | 86 | 94 | 121 | 59 | 154 | 29 | 322 |
| EPS (₹) | −0.62 | 3.59 | −0.48 | 103.00 | 1.94 | 1.14 | 1.58 | 1.65 | 2.12 | 1.01 | 2.71 | 0.31 | 3.01 |
| YoY Sales growth | −67 | −70 | 21 | 19 | 17 | 10 | 3 | 8 | 10 | 13 | 18 | 22 | 136 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 2,994 | 3,699 | 4,138 | 4,643 | 6,508 |
| Expenses | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 2,547 | 3,124 | 3,383 | 3,769 | 5,170 |
| Operating Profit | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 447 | 575 | 756 | 875 | 1,338 |
| OPM % | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 15% | 16% | 18% | 19% | 21% |
| Other Income | 23 | 25 | 453 | 177 | −155 | −158 | 53 | 51 | 353 | 32 | 5,168 | 91 | −9 |
| Interest | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 132 | 212 |
| Depreciation | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 264 | 354 |
| PBT | 306 | 38 | 108 | 305 | 410 | 330 | 205 | 636 | 511 | 268 | 5,542 | 570 | 764 |
| Tax % | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 7% | 21% | 2% | 25% | — |
| Net Profit | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | 5,408 | 427 | 564 |
| EPS (₹) | 5.83 | 0.18 | 2.18 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 | 107.66 | 7.49 | 7.04 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 5% | 40% | — |
| Sales growth | 35 | 35 | 13 | 13 | 18 | 9 | 0 | 19 | −71 | 24 | 12 | 12 | 50 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 | 518 | 872 |
| Reserves | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,686 | 2,554 | 3,683 | 6,919 |
| Borrowings | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,758 | 2,392 | 2,594 | 5,940 |
| Other Liabilities | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,039 | 1,154 | 1,280 | 3,792 |
| Total Liabilities | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 8,076 | 17,523 |
| Fixed Assets | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | 3,920 | 4,242 | 12,205 |
| CWIP | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 | 293 | 420 | 529 |
| Investments | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 | 245 | 1,167 | 422 |
| Other Assets | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,620 | 2,142 | 2,248 | 4,366 |
| Total Assets | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 8,076 | 17,523 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 236 | 203 | 361 | 537 | 601 | 1,223 | 1,569 | 1,314 | 1,834 | 158 | 425 | 656 |
| Investing | −439 | −775 | −1,136 | −522 | −702 | −658 | −333 | −563 | −951 | −878 | 6,015 | −288 |
| Financing | 203 | 578 | 654 | 46 | 134 | −675 | −1,116 | −686 | −817 | 1,053 | −6,358 | −304 |
| Net Cash Flow | −1 | 5 | −122 | 61 | 33 | −110 | 120 | 65 | 66 | 332 | 82 | 63 |
| Free Cash Flow | −176 | −536 | −565 | 23 | 64 | 715 | 1,183 | 770 | 995 | −601 | 70 | 179 |
| CFO/EBITDA | 51 | 53 | 116 | 93 | 61 | 88 | 143 | 89 | 424 | 40 | 71 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 285 | 23 | 23 | 24 |
| Inventory Days | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 612 | 44 | 36 | 32 |
| Days Payable | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 1,400 | 183 | 166 | 168 |
| Cash Conversion Cycle | −2 | −1 | 30 | 45 | 50 | −65 | −83 | −66 | −503 | −116 | −107 | −112 |
| Working Capital Days | 69 | 68 | 6 | 59 | 28 | 8 | 5 | 5 | −21 | 272 | −32 | −28 |
| ROCE % | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 3% | 4% | 11% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aster DM Healthcare insights
68 extracted metrics across FY14–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q2 FY27 concall · Nov 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · Jun 2026Transcript PPT
- 6 Nov 2025
- 30 Jul 2025
- 29 Jul 2026
- 3 Oct 2025
- 16 Apr 2024
- 7 Dec 2023
- 20 Oct 2022
Frequently Asked Questions about Aster DM Healthcare
What does Aster DM Quality Care Ltd do?
Where is Aster DM Quality Care Ltd (ASTERDM) listed?
Which sector does Aster DM Quality Care Ltd belong to?
What is the market capitalisation of Aster DM Quality Care Ltd?
What is the PE ratio of Aster DM Quality Care Ltd?
What is the 52-week high and low of Aster DM Quality Care Ltd?
Does Aster DM Quality Care Ltd pay dividends?
What is the Return on Equity (ROE) of Aster DM Quality Care Ltd?
Company Information
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ASTERDM.md for Aster DM Quality Care Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.